SAGE Healthcare Private Limited appointed to serve as a non-exclusive licensee and distributor for Volition's Nu.Q® Vet Cancer Screening Test in centralized labs in Singapore, with launch planned
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of cancers and other
According to Benzinga Pro data, during Q2, VolitionRX (AMEX:VNRX) posted sales of $24.78 thousand. Earnings were up 3.03%, but VolitionRX still reported an overall loss of $5.90 million.